STERIS Director Martin Paul Edward Receives Awards

What Happened

• Martin Paul Edward, a director of STERIS plc (STE), was granted derivative awards on 2026-08-10: 1,506 nonqualified stock options and 512 Career Restricted Stock Units (CRSUs). The filing reports $0.00 per unit for these grants (transaction code A — award/grant).
• The 1,506 instruments are nonqualified stock options that the filing notes are fully vested and exercisable immediately. The 512 units are Career RSUs that are fully vested now but will be settled in STERIS ordinary shares six months after the director ceases Board service. No cash purchase or sale was reported.

Key Details

• Transaction date: 2026-08-10; Form 4 filed: 2026-08-12 (appears filed within the typical 2-business-day window).
• Instruments: 1,506 nonqualified stock options (fully vested/exercisable) and 512 Career RSUs (fully vested; settlement in shares six months after cessation of Board service).
• Reported per-unit acquisition price/value: $0.00 (award/grant). These are derivative awards, not open-market purchases or sales.
• Shares owned after transaction: not specified in the excerpt provided — see the full Form 4 for total beneficial ownership.
• Footnotes: F1 = options fully vested/exercisable immediately; F2/F3 = each Career RSU converts to one ordinary share six months after Board service ends and is fully vested now.

Context

• These were grants/awards (not purchases or sales). Options are exercisable immediately but the filing does not indicate any exercise or sale of resulting shares. Career RSUs will only convert to shares upon the director’s leaving the Board (with a six-month delay), so they do not represent immediate share ownership.
• For retail investors: awards are routine compensation for directors and do not necessarily signal the director’s short-term market view. For full details on ownership and potential dilution, check the complete Form 4 filing.